

# Investigating tranexamic acid for bleeding control in facelift surgery

<b>Submission date</b> 01/11/2025	<b>Recruitment status</b> Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 06/11/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 06/11/2025	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

This randomized controlled trial investigates whether local tranexamic acid (TXA) can reduce intraoperative bleeding and postoperative complications (like hematoma, swelling, and bruising) in patients undergoing facelift (rhytidectomy) surgery at King Abdulaziz University Hospital. TXA is known for minimizing bleeding in surgery, but no RCT has evaluated its local use in facelifts.

### Who can participate?

Healthy adults aged 35 years and older, or those with stable (compensated) medical conditions, who are undergoing facelift surgery.

People are excluded if they are under 35, have bleeding or clotting disorders, take anticoagulants or hormones, or have major organ failure.

### What does the study involve?

Participants are randomly assigned to either:

Intervention group: receive local TXA under the skin flap, or

Control group: receive standard care (lidocaine with epinephrine only).

Bleeding is measured during surgery, and participants attend three follow-up visits (days 1, 6, and 9) and one remote check. Surgeons and patients rate bruising and swelling at each visit.

### What are the possible benefits and risks of participating?

Benefits: TXA may reduce bleeding, bruising, swelling, and overall complications, leading to faster recovery.

Risks: Rare allergic or clotting reactions, nausea, low blood pressure, rash, or visual disturbances. Pregnant or breastfeeding individuals must not participate.

### Where is the study run from?

Conducted at King Abdulaziz University Hospital (KAUH), Riyadh, Saudi Arabia, under King Saud University supervision.

### When is the study starting and how long is it expected to run for?

February 2024 to June 2026

Who is funding the study?  
Investigator initiated and funded

Who is the main contact?  
Principal Investigator:  
Prof. Ahmad Al-Arfaj, aalarrfaj@ksu.edu.sa

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Abdulaziz AlEnazi

**ORCID ID**  
<https://orcid.org/0000-0002-0270-1906>

**Contact details**  
SB-ORLHNS, EBEORL-HNS, ABHS-ORLHNS, JMC-ORL,DOHNS  
Otolaryngology Head Neck & Facial Plastic Surgery,  
Imam Abdulrahman Bin Faisal University.  
Al Khobar  
Saudi Arabia  
34212  
-  
asenazi@iau.edu.sa

**Type(s)**  
Principal investigator

**Contact name**  
Prof Ahmed Alarfaj

**ORCID ID**  
<https://orcid.org/0009-0009-5436-3660>

**Contact details**  
Facial Plastic Unit  
King Saud University, Riyadh KAUH, ENT Department  
KSU Facial Plastic Fellowship  
Riyadh  
Saudi Arabia  
12629  
-  
aalarrfaj@ksu.edu.sa

**Type(s)**  
Public

**Contact name**

Dr Abdulaziz Alderaywsh

**ORCID ID**

<https://orcid.org/0000-0001-7327-5708>

**Contact details**

Family and Community Medicine King Saud University

Riyadh

Saudi Arabia

12372

-

aalderaywsh@ksu.edu.sa

**Additional identifiers****Clinical Trials Information System (CTIS)**

Nil known

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

E-23-8441

**Study information****Scientific Title**

Effects of local tranexamic acid on bleeding during rhytidectomy and post operative complication: randomized, controlled, single-blind trial

**Acronym**

TXA-Rhytid Trial

**Study objectives**

Determine whether Local TXA has any effect on intraoperative bleeding or postoperative sequelae in patients undergoing a facelift.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 19/02/2024, College of Medicine Institutional Review Board (King Saud University – College of Medicine, Riyadh, 11472, Saudi Arabia; +966 114670011; irbresearch2@gmail.com), ref: E-23-8441

**Study design**

Interventional single blind randomized controlled trial

**Primary study design**

Interventional

## Study type(s)

Prevention

## Health condition(s) or problem(s) studied

Prevention of bleeding and postoperative complication in Rhytidectomy

## Interventions

Control: Tumescant ( 0.5% lidocaine with 1:200,000 epinephrine).

Case: Tranexamic acid (TXA) +Tumescant ( 1 mg/ml TXA and 0.5% lidocaine with 1:200,000 epinephrine)

Administration Rout: Local Infiltration

Randomization of allocation: by using random numbers table generated in the Statistical Package for Social Studies (SPSS v. 21) (SPSS v. 21, IBM Corp., New York, NY, USA)

The total duration of treatment and follow-up will be 1 month

## Intervention Type

Drug

## Phase

Phase III/IV

## Drug/device/biological/vaccine name(s)

Tranexamic acid

## Primary outcome(s)

Certainly, Nicholas. Here's the revised list of outcome measures in the correct format:

1. Intraoperative blood loss is measured using the volume collected in the surgical suction container during surgery
2. Intraoperative blood loss is measured using gravimetric analysis by weighing surgical sponges and gauze before and after use during surgery
3. Postoperative edema is measured using a subjective 3-point scale (mild, moderate, severe) assessed by both patient and surgeon at postoperative visits 1, 6, and 9
4. Postoperative ecchymosis is measured using a subjective 3-point scale (mild, moderate, severe) assessed by both patient and surgeon at postoperative visits 1, 6, and 9
5. Postoperative edema is measured using objective volumetric assessment with Vectra imaging at postoperative visits 1, 6, and 9
6. Postoperative ecchymosis is measured using objective volumetric assessment with Vectra imaging at postoperative visits 1, 6, and 9

## Key secondary outcome(s)

1. Patient satisfaction is measured using the FACE-Q questionnaire at baseline (before procedure) and postoperative day 9
2. Time to drain removal is measured using clinical records at end of study
3. Complications will be assessed at follow up visits:
  - Skin necrosis
  - Hematoma
  - Thromboembolic events
  - Infection

**Completion date**

01/06/2026

## Eligibility

**Key inclusion criteria**

1.  $\geq$  35-year-old
2. Capable for follow up
3. Healthy patients or with compensated comorbidities, after the agreement of the assigned health care team
4. Candidates for cosmetic face and neck surgery
5. Absence of previous surgeries on the face

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

35 years

**Upper age limit**

75 years

**Sex**

All

**Key exclusion criteria**

1.  $<$  35-year-old
2. History of thromboembolic events or seizure
3. History of bleeding disorder
4. Active use of oral contraceptive pills and/or hormone replacement therapy, Aspirin, anti-coagulant, and Omega 3
5. Patient preference
6. Any condition increase edema (Renal failure, heart failure, liver disease)

**Date of first enrolment**

01/05/2024

**Date of final enrolment**

01/05/2026

## Locations

**Countries of recruitment**

Saudi Arabia

**Study participating centre**

**King Abdulaziz University Hospital, King Saud University**

King Abdulaziz Rd, Al Malaz

Riyadh

Saudi Arabia

12629

## Sponsor information

**Organisation**

King Saud University

**ROR**

<https://ror.org/02f81g417>

## Funder(s)

**Funder type**

Other

**Funder Name**

Investigator initiated and funded

## Results and Publications

**Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date

**IPD sharing plan summary**

Data sharing statement to be made available at a later date